The Claim
Photodynamic therapy combined with ranibizumab achieves complete polyp regression in up to 77.8% of treatment-naïve polypoidal choroidal vasculopathy patients, which is significantly higher than the 26.7–34.7% rate observed with ranibizumab monotherapy.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In patients with polypoidal choroidal vasculopathy who have not received prior treatment, combining photodynamic therapy with ranibizumab results in complete polyp regression in up to 77.8% of cases, while ranibizumab alone results in regression in 26.7–34.7% of cases.
See the scientific wording
Photodynamic therapy combined with ranibizumab achieves complete polyp regression in up to 77.8% of treatment-naïve polypoidal choroidal vasculopathy patients, significantly higher than the 26.7–34.7% rate observed with ranibizumab monotherapy, indicating a strong anatomical advantage for combination therapy.
The laser treatment destroys the abnormal blood vessels by triggering a chemical reaction that clots and blocks them, while the injection stops a protein that keeps those vessels growing, so together they completely shut down and eliminate the abnormal vessels more effectively than either alone.
What the research says
1 studyWhen doctors treat a specific eye condition called PCV with both a laser (PDT) and eye injections (ranibizumab), the abnormal blood vessels disappear in nearly 8 out of 10 patients—much more often than with injections alone, which only work in about 1 out of 3 cases.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.